OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

Artificial intelligence (AI) can accelerate drug development, reduce costs, and improve treatment efficacy, but faces challenges like data quality and regulatory hurdles. Over 900 FDA-approved ...

The Computational Analysis of Novel Drug Opportunities (CANDO) platform is a computational approach to make drug discovery faster and less expensive while also being safe and effective. According to ...

Google DeepMind has unexpectedly released the source code and model weights of AlphaFold 3 for academic use, marking a significant advance that could accelerate scientific discovery and drug ...

Avner Schlessinger, PhD, right, working with his lab researchers at Mount Sinai AI Small Molecule Drug Discovery Center in New York City. [Mount Sinai] Most breakthrough discoveries are made based on ...

Over the past year, drug discovery has gotten a massive boost from the CAS BioFinder Discovery Platform, which allows scientists to explore known and predicted data that accelerate the preclinical ...

A new AI tool has been shown to identify treatments designed to reverse disease states in cells up to 25 times quicker, more efficiently and more accurately than previous models. Researchers from ...

New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...